There’s a new COVID-19 variant, here’s what doctors want you to know
When it comes to where the new variant has been detected, right now, it’s more common in Europe. Currently, it’s been detected in Poland, Norway, Luxembourg, Ukraine, and Portugal. But XEC has been detected in other places too, such as China, not to mention the 23 cases that have been detected in U.S. so far, including three in California.
New COVID variant XEC expected to arrive with winter spike in cases
When it comes to where the new variant has been detected, right now, it’s more common in Europe. Currently, it’s been detected in Poland, Norway, Luxembourg, Ukraine, and Portugal. But XEC has been detected in other places too, such as China, not to mention the 23 cases that have been detected in U.S. so far, including three in California.
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...
Californians can request free tests at COVIDtests.gov. The online portal will open in late September, the Health and Human ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
CHMP Recommends Marketing Authorization For Pfizer, BioNTech's Omicron KP.2-adapted COVID-19 Vaccine
(RTTNews) - Pfizer (PFE) and BioNTech SE (BNTX) announced that the CHMP of the European Medicines Agency has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent ...
Healthbeat on MSN1d
NYC health commissioner to resign early next yearSign up to receive Healthbeat’s free New York City newsletter here. Dr. Ashwin Vasan, New York City’s health commissioner, ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback